The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

The U.S. State Department has approved the potential sale of F-16 training and sustainment, along with related equipment, for ...

Alphabet's Google will face a trial in September on antitrust enforcers' proposals to make it sell off part of its ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

India's markets regulator has alleged Pranav Adani, director of several Adani group companies and the nephew of the ...

Canadian oil producer Imperial Oil posted a rise in first-quarter profit on Friday, driven primarily by stronger margins in ...

Euroclear plans to seize and redistribute about 3 billion euros ($3.4 billion) of Russia's funds that are frozen at the ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Viking is developing what might be a game-changing medication in the segment.